Cenobamate: A Review in Focal-Onset Seizures
CNS Drugs · 2025-07 · 39 (7) · 707-719
DOI: 10.1007/s40263-025-01178-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 14.04.2025. Verfasst von Tina Nie und 1 weiteren Autor:innen. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. Hauptthemen laut MEDLINE: Anticonvulsants, Carbamates, Seizures, Chlorophenols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben.
Abstract (Originalsprache)
Cenobamate (Ontozry®) is a once-daily oral antiseizure medication (ASM) approved in the EU for the adjunctive treatment of focal-onset seizures, with or without secondary generalisation, in adults with epilepsy that have not been adequately controlled despite previous treatment with ≥ 2 anti-epileptic drugs. In clinical studies, its short-term use significantly reduced seizure frequency and was associated with significantly higher odds of achieving a ≥ 50% reduction in seizure frequency in adults with uncontrolled focal-onset seizures despite treatment with 1-3 concomitant ASMs. Seizure freedom rates were also improved. All these benefits were sustained over up to 48 months. Cenobamate was generally well tolerated across both the short- and longer-term (up to 94 months) clinical studies, with its low starting dosage (12.5 mg/day) and slow (12-week) titration schedule appearing to result in fewer severe treatment-emergent adverse events (TEAEs) during the titration period. Somnolence, dizziness and fatigue were the most frequently reported TEAEs. The effectiveness and adverse events of cenobamate in real-world studies were consistent with those seen in the clinical studies. Thus, cenobamate continues to represent a useful adjunctive treatment option in adults with uncontrolled focal-onset seizures. Oral cenobamate (Ontozry®) is a once-daily anti-seizure medication (ASM). It is approved in the EU for the adjunctive treatment of focal-onset seizures, with or without secondary generalisation, in adults with epilepsy that have not been adequately controlled despite previous treatment with ≥ 2 anti-epileptic drugs. In clinical studies in adults with uncontrolled focal-onset seizures who are taking 1–3 concomitant ASMs, the short-term use of cenobamate was associated with significant reductions in seizure frequency and significantly higher odds of achieving a ≥ 50% reduction in seizure frequency. Seizure freedom rates were also improved. Benefits were maintained over up to 48 months. Cenobamate was generally well tolerated over the short and longer term (up to 94 months); the most common adverse events (AEs) were sleepiness, dizziness and fatigue. When starting cenobamate, a low starting dose and slow (over 12 weeks) increases in the dose are needed to reduce the occurrence of severe AEs, including drug reactions with eosinophilia and systemic symptoms. The effectiveness and tolerability of cenobamate in clinical practice were consistent with those seen in the clinical studies. Thus, cenobamate continues to represent a useful adjunctive treatment option in adults with uncontrolled focal-onset seizures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Zitieren
APA
Nie, T., & Hoy, S. M. (2025). Cenobamate: A Review in Focal-Onset Seizures. CNS Drugs, 39(7), 707-719. https://doi.org/10.1007/s40263-025-01178-4
Vancouver
Nie T, Hoy SM. Cenobamate: A Review in Focal-Onset Seizures. CNS Drugs. 2025;39(7):707-719. doi:10.1007/s40263-025-01178-4
BibTeX
@article{Nie2025,
author = {Nie, Tina and Hoy, Sheridan M},
title = {Cenobamate: A Review in Focal-Onset Seizures},
journal = {CNS Drugs},
year = {2025},
volume = {39},
number = {7},
pages = {707--719},
doi = {10.1007/s40263-025-01178-4}
}
EUVIMED